

CRYOCOR INC  
Form 8-K  
May 07, 2007

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**Form 8-K**

---

**Current Report Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 7, 2007**

---

**CryoCor, Inc.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of

incorporation)

**000-51410**  
(Commission File Number)

**33-0922667**  
(I.R.S. Employer

Identification No.)

**9717 Pacific Heights Boulevard**

**San Diego, California**  
(Address of principal executive offices)

**92121**  
(Zip Code)

**Registrant's telephone number, including area code: (858) 909-2200**

**Not Applicable.**

(Former name or former address, if changed since last report.)

---

## Edgar Filing: CRYOCOR INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events**

CryoCor has been notified by the Food and Drug Administration, or FDA, that it will convene an Advisory Panel meeting on June 27, 2007, for the purpose of reviewing CryoCor's pre-market approval application, or PMA, for the treatment of atrial flutter.

CryoCor expects that the FDA will make a decision on whether or not to approve CryoCor's PMA for the treatment of atrial flutter in August 2007. There can be no assurance that the FDA will make its decision at that time, or that it will approve the PMA for atrial flutter, or that CryoCor will ever receive approval in the United States for the treatment of atrial flutter.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CryoCor, Inc.**

By: /s/ Gregory J. Tibbitts  
Gregory J. Tibbitts  
Vice President, Finance and Chief Financial Officer

*(Principal Financial and Accounting Officer)*

Date: May 7, 2007